04:30 PM EDT, 06/14/2024 (MT Newswires) -- Galapagos (GLPG) plans to present "encouraging" results from the ongoing phase 1/2 trial of its drug candidate GLPG5101 in non-Hodgkin lymphoma at the congress of the European Hematology Association on Saturday.

The presentation will have safety and efficacy data for GLPG5101 in people with diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma, the company said late Friday in a statement.

At the data cutoff date of Dec. 20, "no unexpected safety findings were observed and treatment with GLPG5101 resulted in high complete response rates in all indications in this heavily pretreated patient population," Galapagos said.

Galapagos shares rose 2.2% in recent after-hours activity. They fell 1.1% in the regular session Friday.

Price: 25.99, Change: +0.55, Percent Change: +2.16